Nanovibronix, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
ENvue Medical, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to the market removal of a key product, while also highlighting ongoing liquidity concerns.
NanoVibronix reports increased Q3 2025 revenue driven by the ENvue merger, despite continued operating losses, a going concern warning, and product withdrawal.
NanoVibronix, Inc. reported a significant increase in net loss and declining revenues for Q2 2025, alongside a recent merger, multiple reverse stock splits, and a product withdrawal.
NanoVibronix's Q1 2025 results reflect the impact of the ENvue merger and a reverse stock split, with increased revenue offset by higher operating expenses and a net loss.
NanoVibronix saw a significant increase in revenue year-over-year but continues to experience net losses and faces substantial doubt about its ability to continue as a going concern.
NanoVibronix saw a significant increase in revenue during the second quarter of 2024, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.
NanoVibronix saw a significant increase in revenue during the first quarter of 2024, but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and a potential arbitration payment.